Marc R. Theoret

Internal Medicine

10 Center Dr Bldg 10CRC
Bethesda, MD 20892

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 116 publications

A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study.

A novel real-world data methodology for lymphoma outcome classification: the real-world Lugano study.

Journal: Journal of comparative effectiveness research

Published: March 12, 2026

US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.

US Food and Drug Administration Approval Summary: Imetelstat for Selected Patients With Low- to Intermediate-1 Risk Myelodysplastic Syndromes With Transfusion-Dependent Anemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 24, 2025

Totality of the Evidence: Optimizing Dosage Selection Strategies in Oncology.

Totality of the Evidence: Optimizing Dosage Selection Strategies in Oncology.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 24, 2025

The BCR-SEQC initiative.

The BCR-SEQC initiative.

Journal: Nature immunology

Published: June 13, 2025

Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.

Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 19, 2025

Machine learning reveals distinct T-cell receptor clusters in plasma cell dyscrasias compared to healthy controls.

Machine learning reveals distinct T-cell receptor clusters in plasma cell dyscrasias compared to healthy controls.

Journal: PloS one

Published: April 22, 2025

FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma.

FDA Approval Summary: Lisocabtagene Maraleucel for Relapsed or Refractory Follicular Lymphoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: April 07, 2025

FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy.

FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 26, 2025

FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation.

FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 19, 2025

FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy.

FDA Approval Summary: Axatilimab for Adult and Pediatric Patients Weighing at Least 40 Kilograms with Chronic GVHD after Two Prior Lines of Systemic Therapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 12, 2025

FDA Approval Summary: Lifileucel for Unresectable or Metastatic Melanoma Previously Treated with an Anti-PD-1-Based Immunotherapy.

FDA Approval Summary: Lifileucel for Unresectable or Metastatic Melanoma Previously Treated with an Anti-PD-1-Based Immunotherapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 11, 2025

Cardiac Adverse Events in Patients Receiving Immune Checkpoint Inhibitors in the Adjuvant Setting: An FDA Pooled Analysis.

Cardiac Adverse Events in Patients Receiving Immune Checkpoint Inhibitors in the Adjuvant Setting: An FDA Pooled Analysis.

Journal: Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc

Published: March 06, 2025

Showing 1-12 of 116

Last Updated: 09/26/2026